title: Induction of differentiation of mouse myeloid leukemia M1 cells by serum of patients with chronic myeloid leukemia.
abstract: We examined the capacities of sera from patients with myeloid leukemia to induce differentiation in mouse myeloid leukemic M1 cells. Higher differentiation-inducing activity (D-activity) was detected in sera of patients with chronic myelomonocytic leukemia or chronic myeloid leukemia (CML) than in sera of patients with acute myeloid leukemia and normal volunteers. The D-activity in the sera was lost on heating the sera at 56 degrees for 30 min. The major peak of D-activity on Sephadex G-200 gel filtration had an apparent molecular weight of 160,000. The origin of the D-activity in sera of patients with CML was studied by culturing fractions of peripheral blood cells of patients with D-activity for 3 days and then measuring the ability of the conditioned medium (CM) to induce differentiation of M1 cells. The cells in the myeloblast and promyelocyte fraction differentiated spontaneously into macrophage-like cells during culture for 3 days and the cells in the late granulopoietic cell fraction differentiated into neutrophil-like cells. Higher D-activity was present in CM of cells in the myeloblast and promyelocyte fraction than in CMs of late granulopoietic cell fractions. These results suggest that human leukemic cells produce D-activity for M1 cells during their differentiation into macrophage-like cells.
authors.affiliation: Saitama Cancer Center, Ina.
authors.forename: J
authors.initials: J
authors.lastname: Okabe-Kado
authors.forename: Y
authors.initials: Y
authors.lastname: Honma
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
authors.forename: M
authors.initials: M
authors.lastname: Hozumi
authors.forename: K
authors.initials: K
authors.lastname: Sampi
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: K
authors.initials: K
authors.lastname: Hino
authors.forename: N
authors.initials: N
authors.lastname: Tsuruoka
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects*; D003470:Culture Media; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood*; D007951:Leukemia, Myeloid / Q000473:pathology*; D015477:Leukemia, Myelomonocytic, Chronic / Q000097:blood; D008222:Lymphokines; D008264:Macrophages / Q000473:pathology; D051379:Mice; D010835:Phytohemagglutinins / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D003470:Culture Media; D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; C507838:Lif protein, mouse; D008222:Lymphokines; D010835:Phytohemagglutinins; D013755:Tetradecanoylphorbol Acetate